Click to Learn More About AtriCure
AtriClip
LAA Exclusion System, the most widely implanted LAA management
Insist on Eliminating the Source!
Don’t Just Manage the Risk,
device globally (50,000+), specifically indicated for LAA exclusion.
Synergy
for the treatment of Persistent
The first and only device approved
and Longstanding Persistent Afib
Invest in the Global Leader
In Afib Solutions
Join Our
World Class Team
cryoanalgesia.jpg
cryoICE Cryoanalgesia
for Thoracotomy Procedures
Take Pain OUT of the Procedure

AtriCure: Committed to Atrial Fibrillation Treatment and Solutions

AtriCure is your partner in atrial fibrillation solutions. Our research and rigorous atrial fibrillation clinical trials have led to innovations in ablation technology to treat atrial fibrillation with lasting solutions. Our Synergy Ablation System is the first and only device approved by the Food and Drug Administration for the surgical treatment of persistent atrial fibrillation and longstanding persistent atrial fibrillation in patients undergoing open heart procedures simultaneously. AtriCure also pioneered the AtriClip® LAA Exclusion System, the most widely placed left atrial appendage device worldwide. It is our passion to collaborate with surgeons to make surgeries like the Maze IV simpler to perform and be reproducible by more doctors around the world. Through continued commitment to product innovation and education grounded in clinical science, we’re working to reduce the global atrial fibrillation epidemic.

National News

AtriCure to Announce Fourth Quarter and Full Year 2015 Financial Results

02.01.2016
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 1, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, will release its financial results for the fourth quarter and full year 2015 on Tuesday, February 23, 2016. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, February 23, 2016 to discuss its fourth quarter and full year 2015 financial results. A live webcast of the conference call will be available online on the Investor page of AtriCure’s corporate website at www.atricure.com. You may also access this call through...

Read More

International News

AtriCure Announces Approval for the AtriClip in Japan

01.19.2016
Approval opens up a new market for the most widely implanted left atrial appendage occlusion device in the world WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 19, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for its AtriClip™ products, which includes the AtriClip™ Standard and the AtriClip Pro™ devices. “We are excited to bring the AtriClip to Japan,” said Mike Carrel, President and CEO of AtriCure. “...

Read More